{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:37Z","timestamp":1793370817209,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinbiochem.2026.111138","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:20:00Z","timestamp":1778023200000},"page":"111138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Direct serum biomarkers of liver fibrosis in metabolic dysfunction-associated steatotic liver disease: A scoping review"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-0936","authenticated-orcid":false,"given":"Valentina","family":"Pecoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Trenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2026.111138_b0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111138_b0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111138_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0020","doi-asserted-by":"crossref","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2 (10) (2019) e1912565. doi: 10.1001\/jamanetworkopen.2019.12565.","DOI":"10.1001\/jamanetworkopen.2019.12565"},{"issue":"30","key":"10.1016\/j.clinbiochem.2026.111138_b0025","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.3748\/wjg.v18.i30.3945","article-title":"Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease","volume":"18","author":"Bar\u0161i\u0107","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111138_b0030","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive Diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111138_b0035","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0083","article-title":"Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression","volume":"4","author":"Nallagangula","year":"2017","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1440-1746.2010.06612.x","article-title":"Biomarkers of liver fibrosis","volume":"26 85)","author":"Adams","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0045","doi-asserted-by":"crossref","unstructured":"Peters MD, Godfrey C, McInerney P, et al. Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. 2020.","DOI":"10.46658\/JBIRM-20-01"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111138_b0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0055","article-title":"Clinical importance of laboratory biomarkers in liver fibrosis","volume":"32","author":"Aleknavi\u010di\u016bt\u0117-Valien\u0117","year":"2022","journal-title":"Biochem Med (zagreb)"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4137\/BMI.S10009","article-title":"Molecular Serum Markers of Liver Fibrosis","volume":"7","author":"Liu","year":"2012","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0065","doi-asserted-by":"crossref","unstructured":"McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 75 (2016) 40-6. doi: 10.1016\/j.jclinepi.2016.01.021.","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0070","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https:\/\/doi.org\/10.46658\/JBIMES-20-08.","DOI":"10.46658\/JBIRM-17-06"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15403\/jgld.2014.1121.yad","article-title":"Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease","volume":"24","author":"Aida","year":"2015","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1590\/S0100-879X2005000500012","article-title":"Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease","volume":"38","author":"Santos","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111551","article-title":"Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice\u2013an exploratory case-control study","author":"Dvorak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0090","doi-asserted-by":"crossref","first-page":"13920","DOI":"10.3748\/wjg.v20.i38.13920","article-title":"Real time shear wave elastography in chronic liver diseases: accuracy for predicting liver fibrosis, in comparison with serum markers","volume":"20","author":"Jeong","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0095","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1440-1746.2006.04447.x","article-title":"Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease","volume":"21","author":"Kaneda","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1478-3231.2006.01312.x","article-title":"Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease","volume":"26","author":"Lydatakis","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/hepr.12710","article-title":"Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers","volume":"47","author":"Mizuno","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00535-017-1355-9","article-title":"A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis","volume":"53","author":"Okanoue","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/a-0713-1330","article-title":"Noninvasive Liver Fibrosis Tests in patients with Nonalcoholic Fatty Liver Disease: an External Validation Cohort","volume":"51","author":"Polyzos","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.v11.i2.255","article-title":"Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sakugawa","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0125","first-page":"678","article-title":"Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH)","volume":"53","author":"Sasaki","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.08.070","article-title":"Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease","volume":"20","author":"Stefano","year":"2021","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0135","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1478-3231.2005.01064.x","article-title":"Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"25","author":"Suzuki","year":"2005","journal-title":"Liver Int."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.26030","article-title":"Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Tanwar","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00535-007-2014-3","article-title":"Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage","volume":"42","author":"Yoneda","year":"2007","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0150","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease: current status and future perspective","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111138_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Reports"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0160","unstructured":"Royal Australian College of General Practitioners. Metabolic dysfunction-associated fatty liver disease (MAFLD): a consensus statement. East Melbourne (AU): RACGP; 2021. Available from: https:\/\/www.racgp.org.au\/getmedia\/85611838-c30e-41ba-9840-749834be058b\/MAFLD.pdf.aspx."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0170","first-page":"115","article-title":"Serum biomarkers for liver fibrosis assessment. Adv","author":"Maroto-Garc\u00eda","year":"2023","journal-title":"Lab. Med."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0175","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0180","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol (2024) S0168-8278(24)00329-5. doi: 10.1159\/000541386.","DOI":"10.1159\/000541386"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0185","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3748\/wjg.v30.i25.3143","article-title":"Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: an unmet clinical need","volume":"30","author":"Borriello","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0190","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3748\/wjg.v30.i10.1393","article-title":"Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease","volume":"30","author":"Zeng","year":"2024","journal-title":"World J. Gastroenterol."},{"issue":"11\u201312","key":"10.1016\/j.clinbiochem.2026.111138_b0195","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s12272-025-01574-w","article-title":"Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials","volume":"48","author":"Liu","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.clinbiochem.2026.111138_b0200","doi-asserted-by":"crossref","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. (2024) 497-509. doi: 10.1056\/NEJMoa2309000.","DOI":"10.1056\/NEJMoa2309000"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0205","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/metabo13111115","article-title":"Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease","volume":"13","author":"G\u00eelc\u0103-Blanariu","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/prca.201000073","article-title":"Taking a new biomarker into routine use\u2013a perspective from the routine clinical biochemistry laboratory","volume":"4","author":"Sturgeon","year":"2010","journal-title":"Proteomics Clin App"},{"key":"10.1016\/j.clinbiochem.2026.111138_b0215","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat. Med."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:54:53Z","timestamp":1793368493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912026000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S0009912026000664"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111138","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct serum biomarkers of liver fibrosis in metabolic dysfunction-associated steatotic liver disease: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111138"}}